{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:26:30Z","timestamp":1787761590728,"version":"build-2784847793"},"reference-count":114,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation\u2019s biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018079","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T21:02:37Z","timestamp":1764795757000},"page":"1591-1602","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop"],"prefix":"10.1182","volume":"10","author":[{"given":"Reid","family":"Merryman","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-7727","authenticated-orcid":false,"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"4Center for Blood Cancer, Perlmutter Cancer Center New York University School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"5Southwest Oncology, CommonSpirit Mercy, Durango, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"6Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Timmerman","sequence":"additional","affiliation":[{"name":"7Division of Hematology & Oncology, University of California Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"9Lymphoma Research Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-9229","authenticated-orcid":false,"given":"Wendy","family":"B\u00e9guelin","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James","family":"Cerhan","sequence":"additional","affiliation":[{"name":"11Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Green","sequence":"additional","affiliation":[{"name":"12Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"13Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":false,"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[{"name":"14Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian","family":"Link","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Oncology and Bone Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"16Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Nadel","sequence":"additional","affiliation":[{"name":"17Aix-Marseille University, CNRS, INSERM, Centre d\u2019Immunologie de Marseille-Luminy, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-8967","authenticated-orcid":false,"given":"Andrea J.","family":"Radtke","sequence":"additional","affiliation":[{"name":"18Leica Microsystems Inc, Wetzlar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Sehn","sequence":"additional","affiliation":[{"name":"19Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"23Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-7370","authenticated-orcid":false,"given":"Laura","family":"Pasqualucci","sequence":"additional","affiliation":[{"name":"20Institute for Cancer Genetics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY"},{"name":"21Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY"},{"name":"22Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"20","key":"2026030916213177400_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","article-title":"Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin\u2019s lymphoma","volume":"307","author":"Yunis","year":"1982","journal-title":"N Engl J Med"},{"issue":"1","key":"2026030916213177400_bib2","first-page":"3","article-title":"Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma","volume":"2","author":"Tsujimoto","year":"1987","journal-title":"Oncogene"},{"issue":"2","key":"2026030916213177400_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"2026030916213177400_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","article-title":"Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression","volume":"3","author":"Han","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"7337","key":"2026030916213177400_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2026030916213177400_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"2026030916213177400_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","article-title":"Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma","volume":"10","author":"Mondello","year":"2020","journal-title":"Cancer Discov"},{"issue":"31","key":"2026030916213177400_bib8","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"32","key":"2026030916213177400_bib9","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026030916213177400_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2026030916213177400_bib11","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026030916213177400_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"6","key":"2026030916213177400_bib13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-23-0111","article-title":"Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors","volume":"13","author":"Schroers-Martin","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2026030916213177400_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/his.15344","article-title":"Follicular lymphoma research: an open dialogue for a collaborative roadmap","volume":"86","author":"Collin","year":"2025","journal-title":"Histopathology"},{"issue":"6","key":"2026030916213177400_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.2022018719","article-title":"Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns","volume":"142","author":"Dreval","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026030916213177400_bib16","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41588-023-01561-1","article-title":"Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression","volume":"55","author":"Leeman-Neill","year":"2023","journal-title":"Nat Genet"},{"issue":"3","key":"2026030916213177400_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"issue":"36","key":"2026030916213177400_bib18","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","article-title":"Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth","volume":"114","author":"Hashwah","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2026030916213177400_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"2026030916213177400_bib20","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2026030916213177400_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"B\u00e9guelin","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2026030916213177400_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"issue":"3","key":"2026030916213177400_bib23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"},{"issue":"3","key":"2026030916213177400_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2024.02.001","article-title":"Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients","volume":"42","author":"Radtke","year":"2024","journal-title":"Cancer Cell"},{"issue":"9","key":"2026030916213177400_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ccell.2024.05.011","article-title":"Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma","volume":"42","author":"Sarkozy","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"2026030916213177400_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"2026030916213177400_bib27","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"2026030916213177400_bib28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"28","key":"2026030916213177400_bib29","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026030916213177400_bib30","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"13","key":"2026030916213177400_bib31","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"15","key":"2026030916213177400_bib32","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"2026030916213177400_bib33","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026030916213177400_bib34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.23.01912","article-title":"Long-term follow-up of the RESORT study (E4402): a randomized phase III comparison of two different rituximab dosing strategies for low-tumor burden follicular lymphoma","volume":"42","author":"Kahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026030916213177400_bib35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"2026030916213177400_bib36","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026030916213177400_bib37","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM Study","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"},{"issue":"19","key":"2026030916213177400_bib38","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"2026030916213177400_bib39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"2026030916213177400_bib40","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026030916213177400_bib41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026030916213177400_bib42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/bloodadvances.2023011305","article-title":"Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience","volume":"8","author":"Shotton","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2026030916213177400_bib43","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026030916213177400_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/cid\/ciy458","article-title":"Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine","volume":"68","author":"Fung","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2026030916213177400_bib45","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2026030916213177400_bib46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026030916213177400_bib47","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/cancers16071285","article-title":"Comparing R-bendamustine vs. R-CHOP plus maintenance therapy as first-line systemic treatment in follicular lymphoma: a multicenter retrospective GELTAMO Study","volume":"16","author":"Bastos-Oreiro","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026030916213177400_bib48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2026030916213177400_bib49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-024-01111-w","article-title":"Identification of genetic subtypes in follicular lymphoma","volume":"14","author":"Shelton","year":"2024","journal-title":"Blood Cancer J"},{"issue":"24","key":"2026030916213177400_bib50","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood.2024024496","article-title":"Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance","volume":"144","author":"Laurent","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026030916213177400_bib51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41590-018-0181-4","article-title":"Human germinal center transcriptional programs are de-synchronized in B cell lymphoma","volume":"19","author":"Milpied","year":"2018","journal-title":"Nat Immunol"},{"issue":"5","key":"2026030916213177400_bib52","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2026030916213177400_bib53","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026030916213177400_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026030916213177400_bib55","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular lymphoma evaluation index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2026030916213177400_bib56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/bloodadvances.2022007949","article-title":"Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy","volume":"7","author":"Rodr\u00edguez-Sevilla","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026030916213177400_bib57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation tatus may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood"},{"issue":"29","key":"2026030916213177400_bib58","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9383","key":"2026030916213177400_bib59","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"2026030916213177400_bib60","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026030916213177400_bib61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-scalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026030916213177400_bib62","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026030916213177400_bib63","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026030916213177400_bib64","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2026030916213177400_bib65","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood-2022-158232","article-title":"Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R2) for first-ine treatment of follicular lymphoma: initial results from phase 1\/2 trial","volume":"140","author":"Falchi","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026030916213177400_bib66","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2023-174432","article-title":"Preliminary findings of a phase Ib\/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (M + Len) in previously untreated (1L) follicular lymphoma (FL)","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026030916213177400_bib67","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2023-179906","article-title":"Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2026030916213177400_bib68","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026030916213177400_bib69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026030916213177400_bib70","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.1992.10.6.942","article-title":"Survival after relapse of low-grade non-Hodgkin\u2019s lymphoma: implications for marrow transplantation","volume":"10","author":"Weisdorf","year":"1992","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026030916213177400_bib71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/annonc\/mdf119","article-title":"Survival after progression in patients with follicular lymphoma: analysis of prognostic factors","volume":"13","author":"Montoto","year":"2002","journal-title":"Ann Oncol"},{"issue":"11","key":"2026030916213177400_bib72","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"2026030916213177400_bib73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026030916213177400_bib74","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026030916213177400_bib75","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"issue":"7","key":"2026030916213177400_bib76","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"2026030916213177400_bib77","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1097\/HS9.0000000000000838","article-title":"Survival by first-line treatment type and timing of progression among follicular lymphoma patients: a national population-based study in Sweden","volume":"7","author":"Weibull","year":"2023","journal-title":"Hemasphere"},{"key":"2026030916213177400_bib78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","article-title":"Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","volume":"126","author":"Batlevi","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026030916213177400_bib79","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.2147\/CMAR.S309092","article-title":"Real-world, single-center data for lenalidomide plus rituximab in relapsed or refractory diffuse large B-cell lymphoma and transformed follicular lymphoma","volume":"13","author":"Lee","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2026030916213177400_bib80","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.18522","article-title":"Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome","volume":"200","author":"Munta\u00f1ola","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2026030916213177400_bib81","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026030916213177400_bib82","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group","volume":"31","author":"Villa","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026030916213177400_bib83","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2026030916213177400_bib84","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"suppl 1","key":"2026030916213177400_bib85","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1182\/blood-2023-179650","article-title":"Patterns of care and prognostic modeling following follicular lymphoma transformation to aggressive B-cell lymphoma: an analysis from the LEO consortium","volume":"142","author":"Day","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2026030916213177400_bib86","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026030916213177400_bib87","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol"},{"issue":"33","key":"2026030916213177400_bib88","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026030916213177400_bib89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026030916213177400_bib90","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026030916213177400_bib91","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","article-title":"Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the groupe d\u2019Etude des lymphomes de l\u2019Adulte","volume":"17","author":"Decaudin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026030916213177400_bib92","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3324\/haematol.2023.284538","article-title":"Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study","volume":"109","author":"Barraclough","year":"2024","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026030916213177400_bib93","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/blood-2023-186684","article-title":"The FLIPI24 prognostic model identifies poor outcomes in non-immunochemotherapy treated patients with follicular lymphoma","volume":"142","author":"Casulo","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026030916213177400_bib94","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026030916213177400_bib95","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/bjh.19449","article-title":"Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: a systematic review and meta-analysis","volume":"204","author":"Milrod","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"2026030916213177400_bib96","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026030916213177400_bib97","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1007\/s12325-024-02882-1","article-title":"Quality of life evaluation in patients with follicular cell lymphoma: a real-world study in Europe and the United States","volume":"41","author":"Johnson","year":"2024","journal-title":"Adv Ther"},{"issue":"5","key":"2026030916213177400_bib98","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026030916213177400_bib99","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026030916213177400_bib100","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","article-title":"Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy","volume":"126","author":"Zohren","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2026030916213177400_bib101","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1182\/bloodadvances.2020001955","article-title":"Lenalidomide\/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study","volume":"4","author":"Delfau-Larue","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2026030916213177400_bib102","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM Study","volume":"42","author":"Pott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026030916213177400_bib103","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2026030916213177400_bib104","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026030916213177400_bib105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"2026030916213177400_bib106","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/joim.13674","article-title":"Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma","volume":"294","author":"Nagy","year":"2023","journal-title":"J Intern Med"},{"issue":"7","key":"2026030916213177400_bib107","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026030916213177400_bib108","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2022-157194","article-title":"FLIPI24: an improved International Prognostic Model developed on early events in follicular lymphoma","volume":"140","author":"Maurer","year":"2022","journal-title":"Blood"},{"issue":"suppl 2","key":"2026030916213177400_bib109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hon.3163_79","article-title":"A \u201cfunctional cure\u201d may be achievable in a subset of patients with follicular lymphoma treated with chemoimmunotherapy: 15-year follow-up of phase III SWOG-S0016","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematological Oncol"},{"issue":"23","key":"2026030916213177400_bib110","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1182\/bloodadvances.2020003949","article-title":"A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival","volume":"5","author":"Lamaison","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026030916213177400_bib111","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.stem.2024.01.012","article-title":"A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment","volume":"31","author":"Kastenschmidt","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"15","key":"2026030916213177400_bib112","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2024026020","article-title":"Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics","volume":"146","author":"Araujo-Ayala","year":"2025","journal-title":"Blood"},{"issue":"34","key":"2026030916213177400_bib113","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.2217\/fon-2021-0160","article-title":"CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion","volume":"17","author":"Boeri","year":"2021","journal-title":"Future Oncol"},{"issue":"25","key":"2026030916213177400_bib114","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2217\/fon-2022-0421","article-title":"Patient preferences for treatment in relapsed\/refractory diffuse large B-cell lymphoma: a discrete choice experiment","volume":"18","author":"Birch","year":"2022","journal-title":"Future Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1591\/2506235\/blooda_adv-2025-018079-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1591\/2506235\/blooda_adv-2025-018079-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:21:51Z","timestamp":1773087711000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1591\/556936\/Consensus-recommendations-from-the-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018079","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,27]]}}}